ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0664

Which Attributes Are the Most and Least Important to Patients When Considering Gout Flare Burden over Time? A Best-worst Scaling Choice Study

Jeremy Holyer1, William Taylor2, Angelo Gaffo3, Graham Hosie1, Anne Horne1, Borislav Mihov1, Isabel Su1, Gregory Gamble1, Nicola Dalbeth1 and Sarah Stewart1, 1University of Auckland, Auckland, New Zealand, 2University of Otago Wellington, Auckland, New Zealand, 3University of Alabama at Birmingham Medical Centre, Birmingham, AL

Meeting: ACR Convergence 2021

Keywords: gout, Patient reported outcomes

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Several factors contribute to the patient experience of gout flares, including pain intensity, duration, frequency, and disability. It is unknown which of these factors are most important to patients when considering flare burden over time, including those related to the cumulative experience of all flares, or the experience of a single worst flare. This study aimed to determine which flare attributes are the most and least important to the patient experience of flare burden over time.

Methods: Participants were recruited from existing databases of patients who had previously participated in research at the Clinical Research Centre, University of Auckland, Aotearoa/New Zealand. Participants with gout completed an anonymous online survey. Questions were aimed at identifying which attributes of gout flares were the most and least important over a hypothetical six-month period. Four attributes represented the cumulative burden of all flares (average pain of all gout flares, number of gout flares, total number of days of all gout flares, and average difficulty doing usual activities during all gout flares) and three attributes represented the burden of individual flares (pain of the worst gout flare, number of days of the longest gout flare, and difficulty doing usual activities during the worst gout flare). A best-worst scaling method was used to determine the importance hierarchy of the included attributes. Best (B) and worst (W) scores were calculated for each attribute representing the number of times that attribute was chosen as most and least important, respectively. The mean best-minus-worst (BW) score was also calculated to rank the attributes from most to least important, with positive values indicating the attribute being chosen more often as most important, and negative values indicating the attribute being chosen more often as least important.

Results: Fifty participants were included. The majority of participants were New Zealand European middle-aged males and 90% had experienced at least one gout flare in the previous 12 months, with 58% experiencing one to four gout flares in the previous 12 months. Difficulty doing usual activities during the worst flare and pain of the worst flare were ranked as the most important, while average pain of all flares was considered the least important. Overall, attributes related to the single worst gout flare were considered more important than attributes related to the cumulative impact of all flares (Figure).

Conclusion: When thinking about the burden of gout flares over time, patients rank activity limitation and pain experienced during their worst gout flare as the most important contributing factors, while factors related to the cumulative impact of all flares over time are relatively less important. Future studies investigating gout flare prevention should consider capturing outcomes related to the worst gout flare experienced during the follow-up period, specifically those related to activity limitation and pain.

Bar chart showing mean Best-Worst (BW) scores for each attribute. Positive scores indicate that attribute was chosen more frequently as the most important, while negative scores indicate that attribute was chosen more frequently as the least important.


Disclosures: J. Holyer, None; W. Taylor, None; A. Gaffo, None; G. Hosie, None; A. Horne, None; B. Mihov, None; I. Su, None; G. Gamble, None; N. Dalbeth, AstraZeneca, 2, JW Pharmaceutical Corporation, 2, PK Med, 2, Horizon, 2, Selecta, 2, Dyve Biosciences, 2, Arthrosi, 2, Amgen, 5; S. Stewart, None.

To cite this abstract in AMA style:

Holyer J, Taylor W, Gaffo A, Hosie G, Horne A, Mihov B, Su I, Gamble G, Dalbeth N, Stewart S. Which Attributes Are the Most and Least Important to Patients When Considering Gout Flare Burden over Time? A Best-worst Scaling Choice Study [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/which-attributes-are-the-most-and-least-important-to-patients-when-considering-gout-flare-burden-over-time-a-best-worst-scaling-choice-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/which-attributes-are-the-most-and-least-important-to-patients-when-considering-gout-flare-burden-over-time-a-best-worst-scaling-choice-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology